Short Courses and Special Courses
SC49 - Practical Approach to Molecular Diagnosis of Bone and Soft Tissue Tumors
Thursday, March 22, 2018 - 1:00 pm - 4:30 pm
This Short Course session includes up to a half-hour break.
3 CME and 3 SAMs
Judith V.M.G. Bovee, M.D., Ph.D. Department of Pathology, LUMC, Leiden, The Netherlands
Adrian Marino-Enriquez, M.D., Ph.D. Department of Pathology, Brigham and Women's Hospital, Boston, MA
The diagnosis of bone and soft tissue tumors can be very challenging. Up-to-date knowledge of diagnostic and prognostic/predictive molecular markers is crucial to appropriately manage these rare tumors in everyday pathology practice. An integrative approach, overlaying molecular information on top of other clinicopathological variables, allows for a definitive diagnosis of most mesenchymal tumors and improves patient management.
This course aims to provide biological and technical understanding for the practicing pathologist to use appropriate molecular techniques while diagnosing bone and soft tissue tumors. We will discuss the main principles of molecular diagnostics, as well as essential technical aspects of widely-used molecular tests. ‘Real-life’ bone and soft tissue tumor cases including matrix-forming and giant cell-containing bone tumors, small blue round cell sarcomas, vascular tumors, and selected liposarcomas will serve as examples, illustrating specific molecular aberrations and diagnostic techniques that can assist in the sometimes-difficult differential diagnoses.
The course is designed for general practicing pathologists and pathologists-in-training with an interest in molecular diagnostics and/or bone and soft tissue tumors. Pathologists specialized in bone or soft tissue tumors may benefit from the emphasis on specific applications of recently-developed molecular tests including high-throughput, multiplex molecular techniques to specific mesenchymal tumor types, which will be used as prototypical examples. Current concepts of bone and soft tissue molecular tumorigenesis will be introduced during the first half of the course, and practical applications assessing specific tumor types and differential diagnoses will be presented during the second half.
Virtual slides and still images, along with relevant clinical data and molecular test results, will be posted on the USCAP website for review by registrants prior to the meeting. A syllabus will be posted on the USCAP website prior to the meeting, including presentation slides and a reference list. All course registrants will receive web access to the materials presented at the USCAP Annual Meeting along with the text portion of the syllabus.
Upon completion of this educational activity, the learner will be able to:
- Understand the basis of molecular tumorigenesis (how do translocations or mutations cause cancer).
- Understand how these genetic alterations can be detected in tumor tissue.
- Recognize the most common molecular alterations in bone and soft tissue tumors.
Continuing Medical Education and Maintenance of Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 3 SAM credit hours.
Return to 2018 Annual Meeting Short Course Page